bioAffinity Technologies, Inc. (BIAF) is up 124.3% today. Here is some analysis on what might have caused this price movement.
Analysis: The surge appears tied to the company’s March 13 update highlighting record 2025 revenue and unit growth for its flagship CyPath® Lung test, alongside commentary that its lab business was streamlined to focus on higher-margin diagnostic testing. In a small-cap name, a “record” growth headline plus improved operating focus can trigger outsized buying and short-covering.
Details:
Sources:
bioAffinity Technologies Investor Relations, Business Wire
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$BIAF Hedge Fund Activity
We have seen 6 institutional investors add shares of $BIAF stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SABBY MANAGEMENT, LLC removed 242,757 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $286,453
- GEODE CAPITAL MANAGEMENT, LLC added 30,422 shares (+inf%) to their portfolio in Q4 2025, for an estimated $35,897
- IFP ADVISORS, INC removed 25,000 shares (-96.8%) from their portfolio in Q4 2025, for an estimated $29,500
- SCIENTECH RESEARCH LLC removed 16,583 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $19,567
- NORTHERN TRUST CORP added 12,725 shares (+inf%) to their portfolio in Q4 2025, for an estimated $15,015
- CITADEL ADVISORS LLC added 11,631 shares (+inf%) to their portfolio in Q4 2025, for an estimated $13,724
- TWO SIGMA SECURITIES, LLC added 11,125 shares (+inf%) to their portfolio in Q4 2025, for an estimated $13,127
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
